Stride Inc SEC Filings

A shareholder of LRN plans to sell 7,827 shares of common stock under Rule 144, with an aggregate market value of 500,404.37, through Morgan Stanley Smith Barney on the NYSE around 12/15/2025.

The shares come from restricted stock and performance share awards acquired from the issuer in 2017 and 2018. The notice references 43,858,627 common shares outstanding and includes a representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Stride, Inc. reported the results of its annual stockholder meeting held on December 4, 2025. Stockholders approved an amendment and restatement of the company’s 2016 Equity Incentive Award Plan, increasing the number of common shares available for equity awards by 740,000 and extending the plan’s term to October 17, 2035. They also approved a new 2025 Employee Stock Purchase Plan authorizing the issuance of 4,000,000 shares, allowing eligible employees to buy stock at a discount through payroll deductions.

All eight director nominees were elected, and KPMG LLP was ratified as independent auditor for the fiscal year ending June 30, 2026. On an advisory basis, stockholders approved compensation for named executive officers and supported both the updated equity plan and the new employee stock purchase plan by wide voting margins.

Stride, Inc. reported an equity award to one of its non-employee directors in the form of deferred stock units. On 12/04/2025, the director acquired 4,097 deferred stock units under the Stride, Inc. Deferred Compensation Plan for Non-Employee Directors at a price of $0 per unit. Each deferred stock unit is economically equivalent to one share of Stride common stock and becomes payable when the director’s board service ends. These new units will vest on the earlier of December 4, 2026, or the next annual meeting of Stride stockholders. Following this grant, the director beneficially owns 16,955 derivative securities in the form of deferred stock units, held directly.

Stride, Inc.December 4, 2025, the non-employee director received 4,097 Deferred Stock Units (DSUs) under the Stride, Inc. Deferred Compensation Plan for Non-Employee Directors. Each DSU is the economic equivalent of one share of Stride common stock, and any fractional shares will be settled in cash.

The DSUs will vest on the earlier of December 4, 2026 or the next annual meeting of Stride stockholders. After this award, the director beneficially owns 12,333 derivative securities, reported as held directly. The DSUs are payable when the director’s board service ends, so this grant defers compensation into equity aligned with the company’s share performance.

Stride, Inc. reported a routine insider transaction involving one of its directors. On December 4, 2025, the director acquired 4,097 shares of Stride common stock as a restricted stock award at a stated price of $0, reflecting an equity-based compensation grant rather than an open-market purchase.

After this grant, the director beneficially owns 6,359 shares of Stride common stock in direct ownership form. The filing notes that these restricted shares will vest on the earlier of December 4, 2026, or the next annual meeting of Stride’s stockholders, tying the award to continued board service and the company’s regular governance calendar.

Stride, Inc. reported that one of its directors received an award of 4,097 Deferred Stock Units (DSUs) on December 4, 2025 under the Stride, Inc. Deferred Compensation Plan for Non-Employee Directors. Each DSU is the economic equivalent of one share of Stride common stock and is payable after the director’s service ends, with any fractional share settled in cash.

The DSUs will vest on the earlier of December 4, 2026 or the next annual meeting of Stride’s stockholders. Following this grant, the director beneficially owns 13,218 derivative securities related to Stride common stock, held directly.

Stride, Inc. reported that a director received a grant of 4,097 shares of restricted common stock on December 4, 2025 at a price of $0 per share. Following this grant, the director beneficially owns 6,551 shares of Stride common stock in total, held directly. These restricted shares will vest on the earlier of December 4, 2026 or the next annual meeting of Stride’s stockholders, aligning the director’s compensation with the company’s future performance.

Stride, Inc. director reported receiving a grant of restricted common stock. On 12/04/2025, an indirect account, the S&C Fink Living Trust, acquired 4,097 shares of Stride common stock at a stated price of $0, reflecting an equity award rather than an open‑market purchase. After this grant, the trust holds 175,607 shares of Stride common stock indirectly. These restricted shares will vest on the earlier of December 4, 2026, or the next annual meeting of Stride stockholders.

Stride, Inc. reported an equity grant to one of its directors. On December 4, 2025, the director acquired 4,097 shares of Stride common stock at a price of $0, reflecting a restricted stock award rather than an open-market purchase. Following this transaction, the director beneficially owns 42,201 shares, held directly.

The new shares are restricted and will vest on the earlier of December 4, 2026 or the date of the next annual meeting of Stride, Inc. stockholders. This filing is a routine Form 4 disclosure of director equity compensation and does not describe any broader corporate events or financial results.